Bharat Biotech to produce Covaxin in Ankleshwar
Ahmedabad:21.05.2021
Bharat Biotech, the maker of India’s first indigenous Covid-19 vaccine, Covaxin, on Thursday announced that it will utilize its subsidiary Chiron Behring Vaccines’ facility at Ankleshwar in Gujarat to further ramp up its Covaxin production.
Bharat Biotech plans to produce 200 million doses of Covaxin per annum at the Ankleshwar facility and product availability at this plant will commence from the fourth quarter of 2021, the vaccine major said.
Bharat Biotech had already deployed multiple production lines at its Hyderabad and Bengaluru campuses.The Ankleshwar plant will take its overall capacity to produce Covaxin to 1 billion doses per annum. TNN
No comments:
Post a Comment